PharmaJet Inc. has partnered with Immuno Cure to develop a needle-free HIV therapeutic DNA vaccine. The agreement, signed on June 16, 2025, during the BIO International Convention in Boston, will utilize PharmaJet’s Tropis system in a human clinical trial for their ICVAX vaccine. This collaboration follows the success of an earlier Phase 1 trial of…
This Article Is Locked, But Not Out of Reach
Jeffco BdB delivers smart insights on local businesses. Get a free account to unlock rankings, trends, and alerts tailored to you.
Curious how it works? Watch the Quickstart
Want everything unlocked? See Paid Options
Already a member? Log in here